FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Epam Modestly Lowers Fy 26 Revenue Forecast, Offset By Improved Eps View

作者

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

EPAM reported Q1 sales of $1.400B (+8% Y/Y), beating consensus ($1.394B), with organic growth of 3.7% decelerating from 5.6% in Q4 and 7.1% in Q3 but up from 1.4% growth in Q1 2025. Growth was led by Financial Services (+12%) and Software & Hi-Tech (+11%), with Business Information & Media (-0.7%) underperforming. Non-GAAP EPS of $2.86 (+19%) beat expectations ($2.75), with help from operating margin expanding 80 bps Y/Y (to 14.3%) and $324M of share repurchases. Management disappointingly lowered 2026 revenue guidance to a midpoint of 5.25% from a prior view of 6.0% (organic CC 3.75% vs. prior 4.5%) but raised EPS guidance to a midpoint of $13.13 from $12.59 as profitability improves and share count declines. While the lower sales view may fuel bears' AI competition fears, we suspect the downtick relates more to rising macro uncertainty, and we are encouraged by continued efficiency gains. Fixed-price contracts continue rising (21.7% of sales, +260 bps Y/Y), creating opportunities for margin outperformance.

相關文章

Insider Trading

根據最近提交給美國證券交易委員會(SEC)的文件顯示,康斯坦利姆公司內部人士出售了價值822,057美元的股票。

2026年5月5日,執行副總裁兼財務長郭傑克(Jack Q. Guo)出售了Constellium (CSTM)的25,201股股票,套現822,057美元。根據向美國證券交易委員會(SEC)提交的4號表格文件,郭傑克目前控制該公司共計185,368股普通股,其中185,368股為直接持有。 SEC文件連結: https://www.sec.gov/Archives/edgar/data/1563411/000209518226000002/xslF345X05/wk-form4_1778162530.xmlPrice: $33.06, Change: $-0.27, Percent Change: -0.83%

$CSTM
Asia

最新消息:武漢益智生物製藥有限公司(隸屬於中國生物製藥集團)的腹水藥物申請已獲中國受理。

(更新內容包括該藥物的主要研發方武漢益智生物製藥) 武漢益智生物製藥(港交所代號:2496)與中國生物製藥(港交所代號:1177)旗下子公司共同研發的藥物M701的新藥申請已獲中國國家藥品監督管理局受理。 根據週四在香港交易所提交的兩份文件顯示,該藥物用於治療晚期上皮惡性腫瘤引起的惡性腹水。 中國生物製藥旗下子公司正泰天青藥業集團於2024年8月獲得該藥物在中國大陸的獨家可轉授許可,負責該藥物的註冊、研發、生產和銷售。

$HKG:1177$HKG:2496
International

3月份美國建築支出增幅超乎預期,住宅興建增加

美國3月建築支出成長0.6%,高於彭博社先前調查預測的0.2%的增幅,而2月則下降了0.2%。 私人住宅建設成長1.7%,其中獨棟住宅建設成長2.7%,多戶住宅建設成長0.3%,房屋改造成長0.9%。 私人非住宅建設和公共建設均下降0.2%。